On July 2, 2026, Spyre Therapeutics, Inc. (NASDAQ: SYRE) based in Waltham, Massachusetts, disclosed that their Compensation Committee approved the issuance of stock options for the purchase of a total of 58,843 common shares and 2,134 restricted stock units (RSUs) to six non-executive staff members. These equity inducement awards were granted under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan and were considered crucial for the employees' recruitment as per Nasdaq Listing Rule 5635(c)(4). This move aims to enhance the standard of immunology treatments by offering more comprehensive disease management, improved longevity, and a more convenient therapy process for patients.
